Introduction {#sec1}
============

The activation of canonical Wnt/β-catenin pathway controls embryo development and early differentiation events ([@bib29]). However, it can also control the self-renewal and pluripotency of stem cells ([@bib22; @bib45; @bib47]). The activation of this pathway is due to the inhibition of the β-catenin destruction complex formed by APC, GSK3, and AXIN, resulting in β-catenin stabilization. Consequently, β-catenin can then translocate into the nucleus and activate target genes via its association with the TCF factors ([@bib5; @bib16; @bib34]). TCF proteins belong to a family of transcription factors, which include TCF1, LEF1, TCF3, and TCF4. TCF1 and LEF1 can bind β-catenin and activate target genes when the Wnt pathway is active ([@bib16; @bib17; @bib58]). In contrast, when the Wnt pathway is not active, all the TCF factors can recruit repressive complexes and function as repressors of target genes ([@bib4; @bib8]).

Embryonic stem cells (ESCs) cultured in 2i medium, which contains GSK3 and MEK inhibitors, can be propagated in a pluripotent ground state ([@bib46]). Pluripotent ground state is also established by *Tcf3* deletion in ESCs ([@bib7; @bib50; @bib59; @bib60; @bib61]). It is interesting to note that the GSK3 inhibitor in 2i medium stabilizes β-catenin. This suggests that the pluripotent ground state of ESCs can be maintained by derepression of TCF3 but also by activation of the Wnt pathway via stabilization of β-catenin. Moreover, activation of Wnt signaling prevents differentiation of ESCs into epiblast stem cells (epiSCs), through regulation of the transition between the ground and primed states ([@bib53]).

The Wnt/β-catenin pathway can also activate somatic cell reprogramming to pluripotency. Mouse embryonic fibroblasts (MEFs) transduced with retroviruses carrying *Oct4*, *Klf4*, and *Sox2* and cultured in medium containing Wnt3a can generate induced pluripotent stem cell (iPSC) colonies with enhanced efficiency in absence of *c-Myc* ([@bib32]). Furthermore, activation of the Wnt pathway in ESCs enables them to reprogram neural precursor cells after fusion ([@bib26]). Finally, the deletion of *Tcf3* greatly enhances cell-fusion-mediated reprogramming, as well as the production of induced pluripotent stem cells (iPSCs) ([@bib28; @bib37]).

In addition to the Wnt-mediated control of ESC pluripotency and somatic cell reprogramming, Wnt signaling is also a driver of differentiation during early developmental phases ([@bib49]). Anterior-posterior axis specification in the mouse embryo occurs through the activity of Wnt signaling ([@bib33; @bib47]). In particular, Wnt signaling activity is essential for establishment of the primitive streak and anterior-posterior polarity, i.e., for epithelial-to-mesenchymal transition of epiblast cells in the primitive streak ([@bib19; @bib35; @bib51; @bib52]).

These apparently opposite roles of the Wnt signaling pathway are therefore a conundrum; on one hand, Wnt activity controls ESC pluripotency, and on the other hand, it regulates early developmental differentiation events. To reconcile these opposite functions, one reasonable hypothesis is based on the level of activation of the Wnt pathway in time. It is well known that Wnt signaling oscillates during development and that its target genes have an oscillatory behavior ([@bib47; @bib55]). At the same time, cyclic activation of the Wnt/β-catenin pathway is essential for enhancing somatic cell reprogramming ([@bib25; @bib26]). If β-catenin activity is either high or very low, reprogramming does not take place. We therefore wondered whether the activation of Wnt signaling activity mediated by TCF factors is essential in a specific phase of the reprogramming of MEFs into iPSCs.

TCF3 and TCF1 share a similar DNA binding domain, and they represent the most highly expressed TCF family factors in ESCs ([@bib28; @bib38]). TCF3 acts as a repressor of Wnt target genes, and in contrast TCF1 can activate or repress Wnt-targets via its association with β-catenin ([@bib4; @bib13]). However, little is known about TCF1 function in ESCs, and here we investigated the role of TCF1 in the reprogramming process of MEFs into iPSCs. Surprisingly, in this context, we found that the activity of the Wnt/β-catenin pathway needs to be switched off during the first days and that the cells undergoing reprogramming have low levels of stabilized β-catenin. Remarkably, sorted Wnt "off" MEFs generate a very high number of NANOG-positive iPSCs. Interestingly, during the early phases of four-factor-induced reprogramming, TCF1 functions as a repressor of Wnt signaling, and this activity correlates with downregulation of senescent genes, such as *p21*, *p19*, and *p16*, and activation of mesenchymal-to-epithelial transition (MET) genes. The activity of the Wnt/β-catenin pathway is instead necessary during the late phases of the reprogramming process.

Results {#sec2}
=======

TCF1 Does Not Control Self-Renewal or Differentiation of ESCs {#sec2.1}
-------------------------------------------------------------

TCF3 is a repressor of pluripotency in ESCs, and its deletion drives the ESCs into a pluripotent ground state ([@bib59; @bib61]). Silencing of *Tcf1* does not affect ESC self-renewal ([@bib61]). Here, we investigated whether TCF1 has a role in controlling mouse ESC differentiation. With this aim, we silenced *Tcf1* in ESCs by infecting the cells with two different lentiviral vectors that carry short hairpins for *Tcf1* (ESCs-shTcf1A, ESCs-shTcf1B) ([Figures S1](#app2){ref-type="sec"}A and S1B available online) and observed that Wnt signaling activity was impaired ([Figure S1](#app2){ref-type="sec"}C). The Wnt signaling activity was measured after activating the pathway with the GSK3 inhibitor BIO in ESCs-shTcf1A, ESCs-shTcf1B, and ESCs-shScr, which were previously infected with a lentivirus carrying the 7xTcf-eGFP reporter (7TGP) for TCF/β-catenin activity ([Figure S1](#app2){ref-type="sec"}C) ([@bib11]). The reporter allowed the measurement of GFP as a Wnt signaling activation readout ([@bib11]). The viruses carrying the short hairpins also carried a hygromicin selection cassette, to allow the selection of the infected cells. Then we analyzed the expression of stem cell genes and self-renewal in ESCs-shTcf1A and ESCs-shTcf1B ([Figure 1](#fig1){ref-type="fig"}A). Expression of *Nanog*, *Stella*, and *Oct4* was not decreased after silencing of *Tcf1*, with respect to cells infected with a virus carrying a scrambled short hairpin (ESCs-shScr), which indicated that the expression of stem cell factors was not affected ([Figure 1](#fig1){ref-type="fig"}A). Finally, we performed clonogenic assays by culturing the same number of ESCs infected with shTcf1A, shTcf1B, and shScr and counting the number of alkaline-phosphatase-positive (AP^+^) colonies, as a marker of pluripotency. The same number of colonies was counted under all three conditions, and their morphologies were indistinguishable ([Figure 1](#fig1){ref-type="fig"}B).

Next, we analyzed the possible defects in the differentiation potential of ESCs silenced for *Tcf1*. For this, we generated embryoid bodies using ESCs-shScr, ESCs-shTcf1A, and ESCs-shTcf1B. We analyzed the expression of pluripotent genes and of mesoderm, ectoderm, and endoderm markers at 3, 5, 7, and 9 days during embryoid body development. Embryoid bodies from both ESCs-shScr and ESCs-shTcf1A developed with the expected morphology at all time points analyzed ([Figure 1](#fig1){ref-type="fig"}C). Pluripotency genes, such as *Oct4*, *Nanog*, and *Rex1*, decreased with the same efficiency and kinetics in both the ESCs-shScr and ESCs-shTcf1A embryoid bodies. Furthermore, the mesoderm markers *Brachyury* and *Flk1*, the ectoderm markers *Fgf5* and *Pax6*, and the endoderm markers *Gata4* and *Foxa2* were expressed with the expected timing at 3, 5, 7, and 9 days of both ESCs-shScr and ESCs-shTcf1A embryoid body development ([Figure 1](#fig1){ref-type="fig"}D). Comparable efficiency of the differentiation potential was also obtained after analyzing the expression of pluripotent genes and of the mesoderm, ectoderm, and endoderm markers during embryoid body development for ESCs-shScr and ESCs-shTcf1B ([Figures S1](#app2){ref-type="sec"}D and S1E).

In all, these data clearly show that silencing of *Tcf1* in mouse ESCs impairs neither self-renewal nor differentiation potential.

Continuous *Tcf1* Silencing Impairs Reprogramming of MEFs to Pluripotency {#sec2.2}
-------------------------------------------------------------------------

Previous studies, including our own, have shown that the activation of Wnt signaling enhances cell-fusion-mediated reprogramming of somatic cells to pluripotency and the efficiency of generation of iPSCs in the absence of c-Myc ([@bib26; @bib32]). Furthermore, derepression of *Tcf3* greatly enhances the reprogramming efficiency of neural precursor cells to pluripotency ([@bib28]). We were next interested in studying the function of TCF1 in the control of somatic cell reprogramming. In addition, because TCF1 controls target genes through its association with β-catenin, in parallel, we investigated β-catenin activity in the regulation of reprogramming.

Thus, we infected doxycycline-inducible four-factor (*Oct4*, *Klf4*, *Sox2*, and *c-Myc*) MEFs ([@bib6]) with shTcf1A, with shTcf1B, with shβ-catenin (shβ-cat), and with control shScr ([Figures S2](#app2){ref-type="sec"}A and S2B). Infected MEFs were selected with hygromycin, replated at equal numbers, and subsequently induced with doxycycline for 12 days. Finally, doxycycline was removed in the last 4 days, and iPSC colonies were analyzed at day 16, by counting the NANOG-positive (NANOG^+^) colonies ([Figure 2](#fig2){ref-type="fig"}A). The number of NANOG^+^ colonies was strongly reduced after both *Tcf1* and *β-catenin* silencing, with respect to the control ([Figures 2](#fig2){ref-type="fig"}B, [S2](#app2){ref-type="sec"}C, and S2D). Furthermore, the few colonies that were formed after *Tcf1* silencing were very small and with little NANOG expression ([Figure 2](#fig2){ref-type="fig"}C). In contrast, shScr-derived iPSCs formed with high efficiency, were positive to alkaline phosphatase (AP), expressed stem cell markers (such as SSEA-1, NANOG, OCT4, SOX2, *Sall1*, and *Rex1*), and differentiated into all three germ layers ([Figures 2](#fig2){ref-type="fig"}D [S2](#app2){ref-type="sec"}E, and S2F). Finally, to exclude adaptation of the MEFs to the loss of *Tcf1*, we infected MEFs with shTcf1A and used doxycyline to induce the four factors at the same time. Also, in this case, we observed a decrease in the NANOG^+^ colonies, although this effect was weaker, as the MEFs were not hygromycin selected ([Figure S2](#app2){ref-type="sec"}G). These data show that continuous silencing of *β-catenin* or *Tcf1* for 16 days impairs reprogramming efficiency.

Inhibition of the Wnt Pathway during the Early Phases Enhances MEF Reprogramming via TCF1 Activity {#sec2.3}
--------------------------------------------------------------------------------------------------

As TCF1 did not appear to have any role in the maintenance of ESC self-renewal, we hypothesized that TCF1 might control reprogramming onset, i.e., the early steps of the process. Thus, we investigated *Tcf1* expression at different time points after doxycycline induction.

THY1 can be followed as an early marker of reprogramming ([@bib3; @bib48]). Cells negative for the expression of this marker 3 days after four-factor induction are enriched in the population undergoing reprogramming ([@bib39]). So four-factor MEFs were induced with doxycycline and sorted by fluorescence-activated cell sorting (FACS) 3, 6, and 9 days after induction for the presence or absence of THY1 ([Figures 3](#fig3){ref-type="fig"}A and [S3](#app2){ref-type="sec"}A). Enrichment of *Thy* expression in sorted cells was confirmed by real-time PCR ([Figure S3](#app2){ref-type="sec"}B). Cells undergoing reprogramming embark into MET ([@bib9; @bib24; @bib44]). Thus, we analyzed expression of epidermal markers, *Epcam* and *Cdh1*, and mesenchymal markers, *Snai1*, *Slug*, and *Vimentin* ([@bib52]). We observed, as previously shown ([@bib39]), that THY1-negative cells undergo efficient MET, as they upregulated *Epcam* and *Cdh1* and downregulated *Snai1*, *Slug*, and *Vimentin*. In contrast, THY1-positive cells maintained the mesenchymal phenotype ([Figure 3](#fig3){ref-type="fig"}B). In addition, the senescence genes *p21*, *p16*, and *p19*, which have been shown to be a barrier to the reprogramming of MEFs into iPSCs ([@bib1; @bib15; @bib21; @bib23; @bib31; @bib54]), were downregulated in the THY1-negative cells ([Figure 3](#fig3){ref-type="fig"}B). Finally, the THY1-negative cells gave rise to fully reprogrammed iPSCs colonies, whereas the THY1-positive cells did not ([Figure 3](#fig3){ref-type="fig"}C).

We found that, while in the THY1-negative cells, *Tcf3* expression remained almost constant at all time points of the reprogramming process, it increased from 6 to 9 days in the THY1-positive cells. This indicates that as expected, cells undergoing reprogramming indeed maintain low levels of Tcf3, the repressor of pluripotency ([@bib28]). In contrast, *Tcf1* expression levels increased progressively from 0 to 6 days in both THY1-positive and THY1-negative cells, before decreasing again in both populations 9 days postinduction (pi) ([Figure 3](#fig3){ref-type="fig"}D).

*Tcf1* has several isoforms, including full-length and ΔN isoforms (*FLTcf1* and Δ*NTcf1*, respectively), which have been extensively studied ([@bib40; @bib56]). ΔNTCF1 was shown to be a repressor, as it lacks the β-catenin binding domain ([@bib43; @bib57]). We therefore investigated which *Tcf1* isoform increases during reprogramming of MEFs. FLTCF1 was greatly increased 6 days pi, as seen using an antibody against FLTCF1 ([Figure 3](#fig3){ref-type="fig"}E). FLTCF1 is also the isoform that is expressed in ESCs. In contrast, ΔNTCF1, which is highly expressed in thymocytes ([@bib18; @bib62]), was not detected during the reprogramming process ([Figure 3](#fig3){ref-type="fig"}E).

Although the expression profile of *Tcf1* was similar in the THY1-positive and THY1-negative cells 6 days pi, the activation of the Wnt signaling pathway was different. Activation of the Wnt pathway, through analysis of the 7TGC reporter activity ([@bib11]), was higher in the THY1-positive cells with respect to the THY1-negative cells ([Figure 3](#fig3){ref-type="fig"}F). Furthermore, expression of the Wnt/β-catenin targets *CyclinD1*, *Axin2*, and *BMP4* was increased in the THY1-positive cells with respect to the THY1-negative cells, with a peak at 6 days pi ([Figure 3](#fig3){ref-type="fig"}G), indicating that Wnt activity is much higher in the THY1-positive cells, which do not undergo reprogramming.

To confirm these observations, we analyzed β-catenin levels in THY1-positive and THY1-negative cells at 6 days pi. Here, active and total β-catenin accumulated more in the THY1-positive cells, clearly indicating that β-catenin can efficiently activate the pathway along with TCF1 in the THY1-positive cells only ([Figures 3](#fig3){ref-type="fig"}H and [S3](#app2){ref-type="sec"}C). In contrast, in the THY1-negative cells, Tcf1 appeared to act as a repressor, as at 6 days postinduction, the Wnt pathway was inactive and β-catenin accumulated much less than in the THY1-positive cells ([Figure 3](#fig3){ref-type="fig"}H). Indeed, when β-catenin does not accumulate, TCF1 acts as a repressor, by binding to corepressor factors, such as members of the Groucho-related family ([@bib41; @bib42]).

To further investigate the repressive activity of TCF1, we overexpressed *Tcf1* in MEFs and analyzed target genes. In particular, for this purpose, we overexpressed *FLTcf1*, which increased during reprogramming, and as a control, *ΔNTcf1*. *Axin2* was drastically downregulated after both *ΔNTcf1* and *FLTcf1* expression respect to the empty vector (E.V.), which indicated that both isoforms repress the Wnt signaling pathway ([Figure 4](#fig4){ref-type="fig"}A). The repressive activity of TCF1 was converted into an activation of the Wnt pathway when Chiron, a GSK3 inhibitor, or Wnt3a were added to the *FLTcf1* infected MEFs. *Axin2* was upregulated upon pathway activation ([Figures S4](#app2){ref-type="sec"}A and S4B).

We observed that the mesenchymal genes *Vim*, *Slug*, and *Snai1* were downregulated by overexpression of both isoforms of *Tcf1* ([Figure 4](#fig4){ref-type="fig"}A). The senescence genes are upregulated in ESCs that express very high levels of β-catenin, resulting in an impairment of cell-fusion-mediated reprogramming ([@bib27]). Therefore, we analyzed their expression after *Tcf1* upregulation. *p21*, *p19*, and *p16* were all downregulated upon *FLTcf1* and Δ*NTcf1* overexpression ([Figure 4](#fig4){ref-type="fig"}A). In contrast, senescence genes and *Snai1* do not change in their expression when the Wnt pathway is activated in shTcf1A-MEFs ([Figure S4](#app2){ref-type="sec"}C). Finally, to determine whether TCF1 directly regulates MET and senescence genes, we performed chromatin immunoprecipitation (ChIP) assays in MEFs, which demonstrated binding of TCF1 to *Snai1*, *p21*, and *Axin2* promoters ([Figure 4](#fig4){ref-type="fig"}B).

Overall, these data indicated that TCF1 can act as a repressor of the Wnt/β-catenin pathway in MEFs, and this results in the repression of some of the mesenchymal and senescent genes.

Next, we investigated whether overexpression of *Tcf1* increased the number of cells undergoing reprogramming. Indeed, we observed a higher number of THY1-negative cells 6 days after infection of four-factor MEFs, compared to EV. ([Figure 4](#fig4){ref-type="fig"}C). Also, these cells showed downregulation of *Axin2* as well as the mesenchymal genes *Vim*, *Snai1*, and *Slug* and the senescence markers *p19* and *p21* ([Figure 4](#fig4){ref-type="fig"}D).

Next, because *Tcf1* increased 6 days pi, we investigated further whether perturbation of *Tcf1* at this time point was essential in the reprogramming process. For this purpose, we infected four-factor MEFs with shTcf1A, shTcf1B, and shScr, selected with hygromycin, induced with doxycycline, FACS sorted the THY1-negative cells 6 days after induction, and plated these cells in equal numbers ([Figure 4](#fig4){ref-type="fig"}E). We observed a reduction in the number of NANOG^+^ clones from the shTcf1-infected MEFs when compared to the control ([Figures 4](#fig4){ref-type="fig"}F and [S4](#app2){ref-type="sec"}D). This shows that silencing the repressive activity of *Tcf1* in THY1-negative cells inhibits the reprogramming process.

To determine whether this effect was dependent on the activation of the MET and/or senescence genes, we analyzed gene expression 6 days after induction in the THY1-negative cells. Interestingly, there was an upregulation of the mesenchymal gene *Snai1* and a downregulation of the epithelial genes *Cdh1* and *Epcam* ([Figure 4](#fig4){ref-type="fig"}G). Moreover, *p21* and *p16* were upregulated 6 days pi in the shTcf1-infected MEFs ([Figure 4](#fig4){ref-type="fig"}G). These data indicate that silencing the repressive activity of TCF1 in the THY1-negative cells in the early phases of reprogramming blocks MET and increases senescence barrier.

Wnt "Off" State Is an Early Reprogramming Marker {#sec2.4}
------------------------------------------------

To further monitor whether Wnt "off" cells in early reprogramming phases embark upon efficient reprogramming, we infected four-factor MEFs with a lentivirus carrying the 7xTcf-eGFP reporter (7TGC) for TCF/β-catenin activity and *mCherry* under the constitutive SV40 promoter ([Figure S5](#app2){ref-type="sec"}A) ([@bib11]). Among the cells that were mCherry positive, four populations of cells with different GFP fluorescence levels were FACS sorted 6 days after doxycycline induction ([Figures 5](#fig5){ref-type="fig"}A and [S5](#app2){ref-type="sec"}B). *Axin2* was analyzed to separate these populations of sorted cells accordingly to the Wnt activity ([Figure S5](#app2){ref-type="sec"}B). GFP^+^ and GFP^−^ cells (fractions P5 and P6), which had the Wnt pathway "on" and "off," respectively, were analyzed for the expression of pluripotency and for MET and senescent genes. As expected, *Axin2*, *CyclinD1*, and *BMP4* were more expressed in the GFP^+^ cells than in GFP^−^ cells. The GFP^−^ cells underwent efficient MET, as they upregulated *Epcam* and *Cdh1* and expressed low levels of *Snai1*, *Vimentin*, and *Slug* with respect to GFP^+^ cells. Also, the senescent gene *p16* and *p19* were downregulated in GFP^−^ cells. Furthermore, the pluripotency markers *Rex1*, *Nanog*, *Oct4*, and *Sall1* were efficiently expressed in GFP^−^ cells ([Figure 5](#fig5){ref-type="fig"}B). Finally, when replated and cultured in presence of doxycycline, only GFP^−^ cells formed a very high number of NANOG^+^ or AP^+^ clones, whereas GFP^+^ cells did not ([Figures 5](#fig5){ref-type="fig"}C, [S5](#app2){ref-type="sec"}C, and S5D). We also analyzed GFP^+^ cells using immunofluorescence and showed that these cells expressed Nestin ([Figure 5](#fig5){ref-type="fig"}D), which suggested they were more differentiated. These results clearly indicate that in the initial steps of the reprogramming process, i.e., up to 6 days after doxycycline induction, the Wnt "off" state is a robust marker of reprogramming.

To further confirm these data, we treated four-factor MEFs for different times with IWP2, an inhibitor of Wnt secretion ([Figure 5](#fig5){ref-type="fig"}E) ([@bib53]). IWP2 treatment for the first 6 days decreased *Tcf1* expression and increased *Tcf3* expression in the whole-cell population. Along with its effects on Wnt secretion, this resulted in inhibition of the activation of the Wnt/β-catenin pathway, as demonstrated by the repression of *Axin2* ([Figure 5](#fig5){ref-type="fig"}F). Together with IWP2, doxycycline induction was applied for 12 days, and the iPSC colonies were analyzed at day 16 (4 days after doxycycline removal) ([Figure 5](#fig5){ref-type="fig"}E). MEFs treated with IWP2 for 6 days expressed high levels of *Nanog*, *Rex1*, and endogenous *Oct4* ([Figure 5](#fig5){ref-type="fig"}F). Furthermore, the number of iPSC colonies was strongly increased when MEFs were treated for the first 3 or 6 days with IWP2 ([Figure 5](#fig5){ref-type="fig"}G). In addition, the silencing of *p21* after IWP2 treatment for 6 days did not result in an increase of reprogramming, further confirming that p21 is an important effector of the Wnt pathway inhibition in the reprogramming process ([Figures S5](#app2){ref-type="sec"}E and S5F). In contrast, treatment of IWP2 from day 6 to day 12 or continuous inhibition of the Wnt pathway with IWP2 strongly reduced the reprogramming efficiency ([Figure 5](#fig5){ref-type="fig"}G). This indicated that the pathway should be inhibited during the first phase of reprogramming and should have a basal activation level during the second phase of reprogramming. To confirm these data, we transfected MEFs with shTcf1 ([Figure S5](#app2){ref-type="sec"}G). In this way, we obtained that shTcf1 was lost within 6 days after induction ([Figure S5](#app2){ref-type="sec"}H), whereas in the infected cells, the silencing was constant for all the reprogramming process ([Figures S5](#app2){ref-type="sec"}J and S5K). We found that whereas the constant inhibition of *Tcf1* resulted in a decreased number of NANOG^+^ colonies ([Figure 2](#fig2){ref-type="fig"}B), *Tcf1* transient inhibition resulted in increased efficiency of reprogramming ([Figure S5](#app2){ref-type="sec"}I).

Activation of the pathway by adding Wnt3a early during the reprogramming process inhibits its efficiency ([Figures 5](#fig5){ref-type="fig"}G and [S5](#app2){ref-type="sec"}L), whereas the addition of Wnt3a late during the reprogramming process only resulted in a slight increase in the reprogramming efficiency ([Figure 5](#fig5){ref-type="fig"}G). In addition, the combined inhibition and activation with IWP2 and Wnt3a during the early and late phases of reprogramming, respectively, moderately increased the efficiency of reprogramming as compared to early inhibition alone ([Figure 5](#fig5){ref-type="fig"}G). This indicates that inhibition of Wnt signaling in the early phase is essential and that a basal activation of Wnt pathway is sufficient during late phases of the reprogramming process ([Figure 5](#fig5){ref-type="fig"}G). Finally, we used two additional inhibitors of the Wnt pathway to treat the MEFs during early reprogramming phases: Dkk1, which acts as Wnt ligand antagonist ([@bib20; @bib36]), and ICRT3, which blocks the interaction between β-catenin and T cell factors ([@bib10; @bib12]). We further confirmed that early inhibition of the pathway results in increased reprogramming efficiency ([Figure S5](#app2){ref-type="sec"}L). Overall, these findings showed that time-dependent perturbation of the Wnt pathway is fundamental to enhance reprogramming efficiency.

Discussion {#sec3}
==========

Earlier we showed that cyclic activation of the Wnt signaling pathway is necessary to enhance cell-fusion-mediated reprogramming ([@bib26]). Also, we showed that finely tuned levels of the Wnt pathway are essential for enhancing somatic cell reprogramming. Too high or too low levels of β-catenin activity result in an impaired reprogramming efficiency ([@bib26]). Here, we demonstrate that, to achieve reprogramming, Wnt signaling needs to be repressed during the early phase of the process and to be active at the late steps; indeed, in a recent interesting study, a similar conclusion was reached ([@bib14]). However, whereas Ho et al. studied prevalently the function of TCF3 in the regulation of reprogramming and focused on the analysis of the whole MEFs population, here we have extensively studied the function of TCF1, demonstrating its essential role during the reprogramming process. In addition, we have characterized the activity of TCF1 in the THY-negative cells, which are the cells that undergo reprogramming. We have shown that TCF1 acts as a repressor of the Wnt signaling pathway at the onset of reprogramming. Furthermore, it promotes repression of senescent genes and activation of MET (by inhibition of transcription of mesenchymal genes and by activation of epidermal genes) in the THY-negative cells, whereas TCF1 acts as an activator in the THY-positive cells that do not undergo reprogramming.

Of note, during the reprogramming process, THY-positive cells represent the majority of the total cell population; therefore, the repressive activity of TCF1 in the THY-negative cells cannot be identified without isolating them.

Finally, by sorting the "Wnt-off" cells, we obtained a striking increase in the number of reprogrammed NANOG^+^ clones, thus clearly identifying the "Wnt-off" state as an early reprogramming marker.

It is interesting to note how different the roles of TCF3 and TCF1 are in the control of somatic cell reprogramming. We showed previously that deletion of *Tcf3* induces increased AcH3 and a decreased number of H3K9me3 heterochromatin foci. These epigenome modifications ultimately enhance reprogramming efficiency ([@bib28]). Here, we showed that the role of TCF1 during the early reprogramming phase is correlated with the repression of senescence genes and with the activation of MET. [@bib14] provided evidence that TCF3 and TCF4 promote early reprogramming events by repressing Wnt pathway target genes, including TCF1 and LEF1. However, they also postulated that TCF3 and TCF4 could control other targets that are independent of TCF1 and LEF1 or of the Wnt pathway activation ([@bib14]). It is tempting to speculate that the latter mentioned might be activated by the epigenetic modifications induced by *Tcf3* derepression.

Very little is known about TCF1 activity in ESCs, although it has been demonstrated that in medium lacking LIF, TCF1 contributes to the effect of Wnt3a stimulation to ESC self-renewal ([@bib61]). Here, we have revealed that in medium containing LIF and serum, wild-type ESCs and ESCs silenced for *Tcf1* do not show differences in self-renewal and differentiation, indicating that TCF1 does not control either process. TCF1 is instead a key regulator of the reprogramming process. This led to the interesting observation that some key transcription factors do not always control both somatic cell reprogramming processes and ESC self-renewal, as the effects on these two processes can be distinct.

Both MET and the downregulation of senescence genes are essential processes to achieve somatic cell reprogramming ([@bib9; @bib30]). Our data show that TCF1 is an important regulator of these processes. Senescent cells are characterized by cell-cycle arrest due to p16^INK4a^ induction. Cell proliferation is crucial in the reprogramming process, and thus cell-cycle arrest is a major barrier to the efficiency of this process. Indeed, mouse fibroblasts cannot be reprogrammed efficiently when two antiproliferative genes, *p16*^*INK4a*^ and *p19*^*ARF*^, which are part of the *lnk4/Arf* locus, are highly expressed. Accordingly, silencing of the *lnk4/Arf* locus restores reprogramming efficiency in senescent cells. Furthermore, knockdown of *p53* and *p21* also accelerates reprogramming of human and mouse fibroblasts ([@bib1; @bib15; @bib21; @bib23; @bib31; @bib54]). Thus, senescence is a barrier to the reprogramming activity, and this can be overcome by TCF1 action, which maintains low expression of *p21* and *p19* during reprogramming.

During MET, SOX2, OCT4, and C-MYC have been shown to supress *Snai1* and TGF-β signaling, whereas KLF4 has been shown to upregulate *E-cadherin* ([@bib24; @bib44]). Here, we found that TCF1 activity is correlated not only with repression of senescence genes, but also with MET activation. Embryoid bodies derived from ESCs undergo epithelial-to-mesenchymal transition in a Wnt-dependent process, with the Wnt activity inducing upregulation of *Snai1* and repression of *E-cadherin* ([@bib52]). It is therefore intriguing that during reprogramming, TCF1 enhances MET by transcriptionally repressing *Vim*, *Slug*, and *Snai1* and upregulating *E-cadherin*. Furthermore, we observed that TCF1 directly represses *Snai1* by binding to its promoter. SNAI1 has been shown to be a transcriptional repressor of *E-cadherin* ([@bib2]). Thus, it might well be that *E-cadherin* is derepressed as a consequence of TCF1-mediated repression of Snai1.

However, we cannot definitively conclude here what the prevalent role of TCF1 is during reprogramming, i.e., if the main function of TCF1 is to modulate senescence genes and MET or also to activate other factors downstream of the Wnt pathway. Finally, it will be particularly interesting to investigate if the Wnt "off" state mediated by the repressive activity of TCF1 is one of the most efficient early reprogramming markers.

Experimental Procedures {#sec4}
=======================

iPSC Induction {#sec4.1}
--------------

The reprogramming experiments were routinely conducted in gelatinized plates, in the ESC culture medium supplemented with 2 μg/ml doxycycline, as described in [@bib6]. Briefly, after doxycycline withdrawal, the cultures were grown in the ESC medium supplemented with 15% FBS. Colonies with ESC morphology were picked 4--6 days after doxycycline withdrawal and grown as iPSC colonies on a feeder layer of MEFs that was inactivated with mitomycin C.

Virus Preparation and MEF Infection {#sec4.2}
-----------------------------------

Lentiviruses were packaged in HEK293T cells. Briefly, the HEK293T cells were cultured in Dulbecco's modified Eagle's medium supplied with 10% FBS (Life Technologies), 10 U/ml penicillin, 10 μg/ml streptomycin, 2 mM glutamine, 1 mM sodium pyruvate, and 1 × nonessential amino acids. For the transfection, 5 × 10^6^ HEK293T cells were seeded onto 10 cm plates and transfected with 10 μg pLKO-shTcf1A, pLKO-shTcf1B, or pLKO-shScr, 6.5 μg pCMV-dR8.9 dvpr, and 3.5 μg pCMV-VSV-G packaging plasmids. After 48 and 72 hr, the supernatants were collected and centrifuged at 20,000 rpm for 1.5 hr at 20°C. The pellet with the viruses was resuspended in PBS (Life Technologies) and stored at −80°C.

For the reprogramming experiments, 2 × 10^5^ MEFs were infected with either pLKO-shTcf1A, pLKO-shTcf1B, or pLKO-shScr in the MEF culture medium. After 48 hr, hygromycin selection (20 μg/ml) was applied for 3--4 days. For iPSC induction, the cells were then plated in equal numbers (5 × 10^4^) onto gelatin-coated six-well plates in the ESC culture medium supplemented with 2 μg/ml of doxycycline.

All animal procedures were approved by the local ethics committee, and met the guidelines of the local and European regulations.
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![Silencing of *Tcf1* in Mouse ESCs Does Not Affect Pluripotency\
(A) Quantitative PCR expression analysis of pluripotent markers *Nanog*, *Stella*, and *Oct4* in ESCs infected with lentiviruses carrying shScr or shTcf1A/B, as indicated. (n = 3, independent experiments).\
(B) Representative colonies of ESCs-shScr and ESCs-shTcf1A/B showing alkaline phosphatase staining (left panels). Quantification on the right shows percentages of alkaline-phosphatase-positive (AP^+^) colonies with respect to all (AP^+^ and AP^−^) colonies (n = 3 independent experiments). Scale bar, 300 μm.\
(C) ESCs-shScr and ESCs-shTcf1A were subjected to differentiation through aggregation into embryoid bodies. Representative phase-contrast images at 3, 5, 7, and 9 days during embryoid body differentiation. Scale bar, 400 μm.\
(D) Representative quantitative real-time PCR experiment (out of three independent experiments) for the detection of *Tcf1*, stem cell (*Oct-4*, *Nanog*, and *Rex1*), ectoderm (*Fgf5*, *Pax6*), mesoderm (*Brachyury*, *Flk1*), and endoderm (*Gata4* and *Foxa2*) marker genes in embryoid bodies at different times pi. The levels are normalized to *Gapdh*.\
All pooled data are represented as means ± SD. See also [Figure S1](#app2){ref-type="sec"}.](gr1){#fig1}

![Silencing of *Tcf1* in Four-Factor-Induced MEFs Impairs Reprogramming\
(A) Experimental scheme for iPSC generation. Four-factor MEFs were infected with lentiviral vectors carrying shScr, shTcf1A, and shβ-catenin. Infected cells were hygromycin selected for 3 days. Doxycycline was applied from 0 to 12 days, to activate expression of *Oct4*, *Klf4*, *Sox2*, and *c-Myc*. Then doxycycline was removed, and cells were allowed to grow for 4 days. At day 16, immunostaining against NANOG was performed, to count the number of reprogrammed clones.\
(B) Number of NANOG-positive (NANOG^+^) clones obtained according to each treatment, as indicated (n = 4 independent experiments).\
(C) Representative image of a NANOG^+^ clone obtained from shScr- and shTcf1-infected MEFs analyzed at day 16.\
(D) Images of immunostaining of iPSC clones obtained from four-factor MEFs infected with shScr. Scale bars, 200 μm (NANOG, OCT4, SSEA1, and SOX2) and 500 μm (AP). Nuclei were stained with DAPI.\
All pooled data are represented as means ± SD. The asterisks indicate statistical significance by t test analysis (n.s., not significant; ^∗^p \< 0.05; ^∗∗^p \< 0.01). See also [Figure S2](#app2){ref-type="sec"}.](gr2){#fig2}

![Time-Dependent Activation of Wnt/β-Catenin Pathway Controls Reprogramming of Four-Factor-Induced MEFs\
(A) Experimental scheme of time course analysis of FACS-sorted cells. Four-factor MEFs were induced with doxycycline as in [Figure 2](#fig2){ref-type="fig"}A. At days 3, 6, and 9, the cells were FACS-sorted for THY1-positive (THY1^+^; blue) and THY1-negative (THY1^−^; red) expression (right panel) and analyzed.\
(B) Time-dependent expression of MET and senescence markers. Relative expression of epithelial markers (*Epcam*, *Cdh1*), mesenchymal markers (*Snai1*, *Slug*, and *Vimentin*), and senescent markers (*p21*, *p16*, and *p19*) in THY1-positive (blue) and THY1-negative (red) sorted cells (n = 3 independent experiments).\
(C) An equal number of THY1-positive (blue) and THY1-negative (red) cells were sorted and plated on feeders at day 6 after doxycycline induction. The number of reprogrammed clones was analyzed using NANOG immunostaining (n = 3 independent experiments).\
(D) Expression of *Tcf3* and *Tcf1* was analyzed in sorted THY1-positive (blue) and THY1-negative (red) cells using quantitative real-time PCR at the indicated days after doxycycline induction (n = 3 independent experiments).\
(E) Schematic representation of the two main TCF1 isoforms. TCF1FL contains a N-terminal β-catenin binding domain (BCBD), whereas TCF1ΔN lacks this domain. Representative western blotting of four-factor MEF extracts on day 0 and day 6 after doxycycline induction. Extracts from ESCs and thymocytes were used as controls. Antibodies against the total TCF1 isoforms and against the full-length TCF1 were used.\
(F) MEFs were infected with 7TGP reporter construct and induced with doxycycline as in [Figure 2](#fig2){ref-type="fig"}A. At days 3, 6, and 9, the cells were analyzed by GFP expression by FACS (n = 3 independent experiments).\
(G) Expression of Wnt/β-catenin target genes (*Axin2*, *CyclinD1*, and *BMP4*) were analyzed in sorted THY1-positive (blue) and THY1-negative (red) cells using quantitative real-time PCR at the indicated days after doxycycline induction (n = 3 independent experiments).\
(H) Representative western blot of active β-catenin in nuclear extracts of THY1-positive and THY1-negative sorted cells 6 days after doxycycline induction.\
All pooled data are represented as means ± SD. The asterisks indicate statistical significance by t test analysis (^∗^ p \< 0.05; ^∗∗^ p \< 0.01). See also [Figure S3](#app2){ref-type="sec"}.](gr3){#fig3}

![TCF1 Is a Repressor of Senescent and Mesenchymal during the First Days of Reprogramming\
(A) Four-factor MEFs were infected with lentiviruses overexpressing either *FLTcf1* or *ΔN-Tcf1*. Infected cells were selected with hygromycin. Four days after infection, the expression of Wnt/β-catenin pathway target (*Axin2*), mesenchymal markers (*Vimentin*, *Slug*, and *Snai1*), and senescence markers (*p21*, *p19*, and *p16*) were analyzed (n = 3 independent experiments). EV, empty vector control.\
(B) Quantitative ChIP assay of the TCF1 targets *Axin2*, *Snai1*, and *p21* in the four-factor MEFs. ChIP was performed using rabbit immunoglobulin G or a specific antibody against TCF1 (n = 2 independent experiments).\
(C) Four-factor MEFs were infected with lentivirus overexpressing *FLTcf1* or with an empty vector (EV) and selected with hygromycin. Six days after doxycycline induction, cells were analyzed by THY1 expression by FACS (n = 3 independent experiments).\
(D) Quantitative real-time PCR expression analysis of empty vector (EV) or *FLTcf1*-overexpressing cells at 6 days after doxycycline induction (n = 3 independent experiments).\
(E) Experimental scheme: four-factor MEFs were infected and treated as in [Figure 2](#fig2){ref-type="fig"}A. THY1-negative cells (THY1^−^) were sorted at day 6 after doxycycline induction, as indicated.\
(F) The same number of THY1-negative cells was sorted at day 6 after doxycycline induction of shScr or shTcf1A-infected four-factor MEFs and plated on feeders. The number of NANOG^+^ clones was determined under each treatment (n = 3 independent experiments).\
(G) Quantitative real-time PCR expression analysis of shScr and shTcf1A-infected, THY1^−^, four-factor MEFs at day 6 after doxycycline induction. The mesenchymal (*Snai1*),; epithelial (*Cdh1*, *Epcam*), and senescence (*p21*, *p16*) genes are analyzed (n = 2 independent experiments).\
All pooled data are represented as means ± SD. The asterisks indicate statistical significance by t test analysis (^∗^ p \< 0.05; ^∗∗^ p \< 0.01). See also [Figure S4](#app2){ref-type="sec"}.](gr4){#fig4}

![Inhibition of the Wnt/β-Catenin Pathway during the First Days of the Reprogramming Process Increases Reprogramming Efficiency\
(A) Four-factor MEFs were infected with lentiviruses carrying 7TGP reporter. GFP^+^ and GFP^−^ cells were sorted 6 days after doxycycline induction. Doxycycline was removed at day 12, and colonies were analyzed at day 16.\
(B) GFP^+^ and GFP^−^ cells were sorted 6 days pi and analyzed by quantitative real-time PCR for the indicated markers (n = 3 independent experiments).\
(C) The number of NANOG-positive clones in GFP^+^- and GFP^−^-sorted cells at day 16 (n = 3 independent experiments).\
(D) GFP^+^ cells were FACS-sorted at day 6 pi, and cells were analyzed by immunofluorescence for the expression of Nestin. Representative images of the immunofluorescence are shown. Scale bars, 100 μm.\
(E) Experimental scheme: four-factor MEFs were treated with doxycycline for 12 days and with IWP2 to inhibit Wnt secretion for the indicated days. At day 16, after doxycycline removal, the colonies were stained for NANOG expression and counted.\
(F) Four-factor MEFs were treated with IWP2 for 6 days. Quantitative real-time PCR of control and treated cells (n = 3 independent experiments).\
(G) The number of NANOG-positive clones in the control and four-factor MEFs treated with IWP2 for the first 3, 4, 6, or 12 days or for the intervals from 6 to 12 or 8 to 12 days as indicated, Wnt3a for the first 4 or 12 days or for the intervals from 8 to 12 days as indicates, or with combination of IWP2 and Wnt3a at the indicated times (n = 3 independent experiments).\
All pooled data are represented as means ± SD. The asterisks indicate statistical significance by t test analysis (n.s., not significant; ^∗^ p \< 0.05; ^∗∗^ p \< 0.01). See also [Figure S5](#app2){ref-type="sec"}.](gr5){#fig5}
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